Novartis receives EU approval for Cosentyx label update

ZURICH (Reuters) - Novartis said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.

The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis, a common, non-contagious, auto-immune disease, the Swiss pharmaceutials company said on Thursday.

(Reporting by Silke Koltrowitz)

Related News

Scarlett Johansson files for divorce, requests custody of daughter

Mar 9, 2017

US-PEOPLE-SCARLETTJOHANSSON:Scarlett Johansson files for divorce, requests custody of daughter

One month in, anti-Trump movement shows signs of sustained momentum

Feb 24, 2017

US-USA-TRUMP-PROTEST:One month in, anti-Trump movement shows signs of sustained momentum

Australians sitting on mountains of cash as wealth outpaces debt

Mar 30, 2017

US-AUSTRALIA-ECONOMY-WEALTH:Australians sitting on mountains of cash as wealth outpaces debt

Must Read

Scarlett Johansson files for divorce, requests custody of daughter

Mar 9, 2017

US-PEOPLE-SCARLETTJOHANSSON:Scarlett Johansson files for divorce, requests custody of daughter

One month in, anti-Trump movement shows signs of sustained momentum

Feb 24, 2017

US-USA-TRUMP-PROTEST:One month in, anti-Trump movement shows signs of sustained momentum

Australians sitting on mountains of cash as wealth outpaces debt

Mar 30, 2017

US-AUSTRALIA-ECONOMY-WEALTH:Australians sitting on mountains of cash as wealth outpaces debt

Search
Top News
You May Need To Know

About Us

Travel Leisure Mag is New York City’s travel and lifestyle online magazine with the vision of creating a unique blend of valuable and quality travel experience to the readers. We trust that you will enjoy this experience.

Contact us: sales@travelleisuremag.com